A phase II study of S-1 in patients with metastatic breast cancer — A Japanese trial by the S-1 cooperative study group, breast cancer working group

This publication has 17 references indexed in Scilit:

• Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats
  Cancer Chemotherapy and Pharmacology, 2000
• Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
  European Journal Of Cancer, 1998
• Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
  Published by Elsevier ,1998
• The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate
  British Journal of Cancer, 1998
• A Comparative, Randomized Trial of UFT® and 5-Fluorouracil in Combination with Cyclophosphamide and Doxorubicin in the Treatment of Advanced Breast Cancer Patients at The Philippines General Hospital
  Oncology, 1997
• Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats
  Cancer Chemotherapy and Pharmacology, 1996
• Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer
  Annals of Oncology, 1996
• Oral tegafur in the treatment of metastatic breast cancer: A phase II study
  European Journal Of Cancer, 1993
• Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and ?-fluoro?-alanine
  Acta Neuropathologica, 1990
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958